Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 25Ovarian Neoplasms 19Neoplasms 12Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 11Endometrial Neoplasms 7Neoplasm Metastasis 6Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Digestive System Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mouth Neoplasms 2Lymphoid Interstitial Pneumonia 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Breast Neoplasms 2Biliary Tract Neoplasms 2Astrocytoma 2

Interventions

Bevacizumab 2repotrectinib 1Oviposition 1Leucovorin 1Irinotecan 1Fluorouracil 1Drug Therapy 1Drainage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Intestinal Neoplasms × Bevacizumab × 30 days × Clear all
NCT03303495 2026-06-05

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Sun Yat-sen University

Phase 3 Recruiting
280 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07222800 2026-06-04

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Pfizer

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Rectal Diseases, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡